Jean Stimola-Sposaro

They accept the clarification as useful and overdue, but argue it stops short: the framework still treats data as something sponsors and investigators divide between themselves, leaving participants out.

• In their argument, protocol-required monitoring data belongs by rights to the person it was gathered from, not to either party.
• They distinguish individual participant health data from study results, noting that even as the NIH pushes for the return of study results, the first category remains undefined.
• They ask whether participant health-data classification should be a mandatory field in protocol design rather than an afterthought.
• The post calls for a patient-preference data-ownership model and a measurable data-integrity framework, then asks what funding the commons would actually require.

The piece Jean commented on, published August 31, 2026, in Applied Clinical Trials, cites ICH GCP E6(R2/R3), MHRA, FDA, and EU CTR 536/2014 to argue that only protocol-required data belongs to the investigator, while kit logistics and quarantine actions remain with the sponsor. Jean’s counterexample is non-exploratory safety data collected for protocol-required monitoring.

Jean treats the regulatory clarification as real progress but argues it leaves the central question untouched: how to give participants a defined place in the ownership model before a trial runs, not after. The tension is between operational clarity for sponsors and investigators and participants’ rights.

Read original

The panel reached at least 80% agreement on 32 of 39 synthesized recommendations.

• Its highest-priority fix was training and support for the healthcare professionals running the trials, not a technology purchase.
• Jean also highlights where consensus broke down: proposals to centralize ethics review at the EU level and enable peer-to-peer participant support failed to reach agreement.
• They read this as a sign that the field has yet to agree on how far harmonization should go and where national and local nuance matters.
• The post ends by asking whether a large consent-stage drop-off reflects a digital-literacy problem, a consent-design problem, or the fact that decentralized and equitable are not automatically the same thing.

The Trials@Home RADIAL study finding cited in the post: 69% of otherwise eligible participants abandoned enrollment at the very first digital consent screen, where they were asked to consent to remote processing of their health data.

• Jean sees this as proof that digital-first design can recreate the access barriers it was meant to remove.
• Murciano-Gamborino et al. published the study in the Journal of Medical Internet Research; the authors and panel produced the consensus results and their interpretation, while Jean posed the framing question at the end.

Read original

They conclude that equitable access requires infrastructure investment in the protocol budget alongside monitoring and site payments—not a recruitment slide or optional patient-support add-on. They ask what it would look like if trial budgets treated caregiver and housing support as required line items.

Jean summarized a September 17 AJMC roundup in which hematologist Dr.

• Karilyn Larkin assessed that relocation costs, time off work, and caregiver demands are bigger barriers to AML clinical trial and stem-cell transplant access than eligibility criteria themselves.
• She said housing and caregiver support would move the needle more than financial-counseling programs alone.
• Larkin’s assessment is hers; the budget line-item argument is Jean’s extension of it.

Read original

The bill targets enrollment barriers that keep racial and ethnic minorities, older adults, and rural populations underrepresented.

• Jean frames it as making equity in access structural rather than aspirational, with policy catching up to the decentralized, digital, and remote-participation tools the field has been building.
• The post asks sponsors already piloting travel or lodging reimbursement what has actually changed in enrollment diversity numbers and what the bill would unlock that voluntary practice cannot.
• In other posts, Jean argues that standards organizations often work in isolation, blocking real-time opportunities to improve trustworthiness, and points to pre-competitive, cross-stakeholder efforts such as the Digital Trials & Research Alliance.

Jean reports that the July 13 endorsement letter for the Clinical Trial Modernization Act drew close to 200 patient advocacy, public health, and healthcare professional groups, including the American Cancer Society Cancer Action Network, the American Lung Association, and the Oncology Nursing Society. The endorsement was the organizations’ action; Jean reads it as policy catching up to technology and puts the question to sponsors.

Read original · Original 2 · Original 3

This is a useful introduction to Jean’s approach: summarize a study, surface the finding that challenges the industry’s preferred framing, and ask what to do next.

Jean summarizes a two-round Delphi study (Murciano-Gamborino et al., 2026, in the Journal of Medical Internet Research) that asked 26 experts across 13 countries to prioritize solutions to six persistent barriers to decentralized clinical trials in Europe: provider burden, investigational product and biosample logistics, collaboration with local healthcare resources, regulatory harmonization, knowledge gaps, and digital technology barriers.

• The panel reached at least 80% agreement on 32 of 39 synthesized recommendations.
• The highest-priority fix was training and support for the healthcare professionals running the trials, not a technology purchase.
• Jean also highlights a finding from the Trials@Home RADIAL study: 69% of otherwise eligible participants dropped out at the first digital consent screen, when consenting to remote processing of health data.
• They argue that digital-first design can recreate the access barriers it was meant to remove.
• Consensus broke down on two proposals—centralizing ethics review at the EU level and enabling peer-to-peer participant support—which Jean reads as evidence that the field has yet to agree on how far harmonization should go.
• The post connects the findings to the Digital Trials & Research Alliance (DTRA) and asks how to classify a 69% consent-stage drop-off: as digital literacy, consent design, or a sign that decentralized and equitable are not automatically the same thing.

For brands planning a campaign

A collaboration on patient-centric trial design can draw on Jean’s ability to work with multistakeholder evidence and turn consensus findings into an uncomfortable, practical question. Expect them to steer discussion toward provider training and consent design rather than new platform features.

Jean responds to an Applied Clinical Trials piece (Aug 31, 2026) that draws a line between investigator-controlled clinical data and sponsor-managed operational data inside interactive response technology systems.

• Citing ICH GCP E6(R2/R3), MHRA, FDA, and EU CTR 536/2014, the piece argues that only protocol-required data belongs to the investigator, while kit logistics and quarantine actions stay with the sponsor.
• Jean calls the clarification overdue and useful, but says it leaves out the participant: non-exploratory safety data collected for protocol-required monitoring belongs by rights to neither the sponsor nor the investigator, but to the person it was gathered from.
• They note that despite momentum from the NIH to embed return of study results, individual participant health data, as distinct from study results, remains an unclear category.
• Jean asks whether participant health-data classification should be a mandatory field in protocol design rather than an afterthought, and calls for alignment on data models for collection, use, and reuse across the patient and product lifecycle.
• They argue that standards organizations often work in isolation, blocking opportunities to improve trustworthiness, and that progress requires a personalized, human-centered patient preference data-ownership model plus a validated, measurable data-integrity framework.
• The post closes by asking what funding the commons would actually look like.

For brands planning a campaign

This post makes Jean’s data-governance position clear.

• A thought-leadership collaboration on data governance should start with their argument for participant ownership and classification in protocol design, not general patient-centricity messaging.
• Expect them to ask who benefits from a proposed data model and whether participants are inside or outside it.

Jean’s recurring argument: logistics, not eligibility criteria, decide who participates.

Jean responds to a September 17 AJMC roundup featuring hematologist Dr.

• Karilyn Larkin, who argues that relocation costs, time off work, and caregiver demands are bigger barriers to AML clinical trial and stem-cell transplant access than eligibility criteria.
• Larkin says housing and caregiver support would move the needle more than financial-counseling programs alone.
• Jean agrees: the field designs statistically elegant eligibility criteria, then underfunds the logistics that determine who can walk through the door.
• They frame equitable access as an infrastructure investment that belongs in the protocol budget alongside monitoring and site payments—not as a recruitment slide or optional patient-support add-on—and ask what it would look like for trial budgets to treat caregiver and housing support as required line items.

For brands planning a campaign

Jean connects access equity to budget decisions.

• A campaign about patient burden should expect them to push for concrete budget lines and operational commitments, not awareness messaging.
• This post is useful to healthcare and clinical-research audiences weighing participation support services.

Jean covers the bipartisan Clinical Trial Modernization Act (S.4440/H.R.3521) and the July 13 letter in which close to 200 patient advocacy, public health, and healthcare professional groups, including the American Cancer Society Cancer Action Network, the American Lung Association, and the Oncology Nursing Society, endorsed it.

• The bill would let sponsors cover non-medical participation costs such as travel, lodging, food, and parking alongside medical copays, and support remote-participation technology.
• It targets enrollment barriers that keep racial and ethnic minorities, older adults, and rural populations underrepresented in trials.
• Jean frames this as making equity in access structural rather than aspirational, with policy catching up to the decentralized, digital, and remote-participation tools the field has been building.
• They also ask sponsors already piloting travel or lodging reimbursement what has actually moved enrollment diversity numbers, and what the bill would unlock that current voluntary practice cannot.
• The post cites the ACS CAN source for the endorsement.

For brands planning a campaign

Jean works at the policy-adjacent layer of trial modernization, connecting legislation, patient advocacy, and operational practice. This post is a useful anchor for collaborations aimed at decision-makers weighing participation costs and remote trial infrastructure.

They highlighted the RADIAL study finding that 69% of otherwise eligible participants abandoned enrollment at the first digital consent screen.

• The panel reached at least 80% consensus on 32 of 39 recommendations, with better training and support for the healthcare professionals running trials ranked highest.
• They also pointed out where consensus failed: proposals to centralize ethics review at the EU level and enable peer-to-peer participant support did not reach agreement, reflecting an unsettled debate over how far harmonization should go.
• Their closing questions ask whether a 69% consent-stage drop-off is a digital-literacy problem, a consent-design problem, or a sign that decentralized and equitable are not automatically the same thing.

Summarizes a peer-reviewed consensus study, names its primary findings and highest-priority recommendation, and flags where expert agreement broke down—not just where it held.

Consensus failures are treated as meaningful information, not smoothed over.

For brands planning a campaign

For a thought-leadership collaboration on patient-centric trial design, this offers a ready-made discussion arc: the data-first case that digital trial design can recreate the access barriers it was meant to remove, followed by the unresolved design and harmonization questions a sponsor audience would debate.

Examples: Source 1

Their main argument was that the framework still treats data as something sponsors and investigators divide between themselves, leaving out the participant.

• They argued that non-exploratory safety data collected for protocol-required monitoring belongs by right to neither party, but to the person it came from.
• They asked whether participant health-data classification should become a mandatory field in protocol design.
• The post also calls for a patient-preference data-ownership model, a measurable data-integrity framework, and a serious answer to what funding the commons would look like.

Uses a published compliance analysis as a starting point, then extends it with a participant-ownership argument and concrete protocol-design questions.

Jean credits the source article's usefulness before challenging its framing, keeping the critique specific rather than dismissive.

For brands planning a campaign

This is the strongest fit for a data-governance collaboration: Jean can move a sponsor conversation past the investigator-versus-sponsor split and toward participant-facing questions of classification, consent, and reuse—the focus of their argument.

Examples: Source 1

In one, Jean Stimola-Sposaro summarized a September 17 AJMC roundup in which hematologist Dr.

• Karilyn Larkin argued that relocation costs, time off work, and caregiver demands are bigger barriers to AML clinical trial and stem-cell transplant access than eligibility criteria, and that housing and caregiver support would move the needle more than financial counseling alone.
• Jean concludes that equity in access is an infrastructure investment that belongs in the protocol budget alongside monitoring and site payments.
• In the other, they covered the bipartisan Clinical Trial Modernization Act (S.4440/H.R.3521), endorsed by nearly 200 patient, public-health, and healthcare professional organizations.
• The act would let sponsors cover non-medical participation costs such as travel, lodging, food, and parking alongside medical copays and support remote-participation technology.

Pairs a clinician's assessment with a live policy endorsement, then turns both into a budget and protocol question for sponsors.

The AJMC post presents Jean's reading of another expert's assessment; the budget recommendation is their own extension.

For brands planning a campaign

A collaboration could focus on the practical line items a sponsor controls, such as travel, housing, and caregiver support, and connect them to the policy layer catching up. Jean asks what would change if trial budgets treated caregiver and housing support as required rather than optional—a concrete campaign angle.

Examples: Source 1 · Source 2

The recurring argument is that participation barriers are structural and underfunded, and that equity must be built into protocol design, data governance, and budgets rather than added later.

• The writing draws on pre-competitive, cross-stakeholder evidence and names alliances and initiatives such as the Digital Trials & Research Alliance (DTRA), with hashtags around equity in access, public health, and public-private alignment.
• One post explicitly invites collaboration with people working on the same problems.

Cites primary or near-primary sources, names the organizations involved, and turns each item into a question its audience can act on or answer.

One post directly asks Jean's network what has moved enrollment diversity numbers, inviting evidence rather than pitching a product.

For brands planning a campaign

A thought-leadership engagement should expect research-led posts with open questions rather than promotional placements. The strongest collaboration fits the pre-competitive framing Jean already uses: joint analysis of a study or policy item, with a practical question for sponsors and patient groups.

Examples: Source 1 · Source 2 · Source 3 · Source 4

They ask which of the 39 recommendations to prioritize first: "We would love to work with you."

View example

Ask Jean what the business does and how they are connected to it; the post does not specify.

View example

Shaddock's Coils to Locs posts describe building a company around a patient experience hospitals did not provide. They name oncology, patient services and hospital retail as their audience—the same people Stimola-Sposaro addresses when arguing that caregiver and housing support belong in a trial budget.

Shaddock documents a company's growth and partnerships, including hospital counts, grants and conference appearances, and makes the case through their sister's and their own founding experience.

• Stimola-Sposaro analyzes published studies, regulation and legislation without describing a product or commercial offer.
• Follow Shaddock for a first-person operational account of fixing a patient-access gap; follow Stimola-Sposaro for evidence and policy on access.

Read original · Original 2

Adenipekun's post on community engagement criticizes healthcare organizations that stop at listening; Stimola-Sposaro's data-ownership post argues that participants are absent from the ownership conversation. Both write about racial health equity, draw on lived experience with cancer and close posts with questions that invite a response.

Adenipekun speaks from lived experience and a trauma-recovery and patient-advocacy standpoint, including in a book on life after trauma, and works at the community-listening and cultural-safety end of the system.

• Stimola-Sposaro draws on published research, regulation and policy, focusing on trial design, data governance and operational budgets.
• Follow Adenipekun for the human and community dimension; Stimola-Sposaro for trial mechanics and governance.

Read original · Original 2

Both frame the problem at the field level, cite specific figures and frameworks, and point to working groups and alliances as places to address it. Mooraj's observation that investors now ask how a therapy will reach a patient is a commercial version of Stimola-Sposaro's point that eligibility criteria mean little if nobody can afford to show up.

Mooraj writes from inside a consulting and advanced-therapies working group about cellular and gene therapy economics: cost of goods, manufacturing, reimbursement models and licensing frameworks such as the EU Clinical Trials Regulation and SOHO.

• A large share of each post goes to thanking participants and conveners.
• Stimola-Sposaro writes about trial-participation logistics, decentralized-trial design and data ownership.
• Follow Mooraj for the commercial and manufacturing side of access; follow Stimola-Sposaro for participation and data governance.

Read original · Original 2

The same clinical research technology company would choose Pamela Shaddock if it wanted a partner who has already built a patient-facing product into hospital operations: since 2019 Pamela Shaddock has co-founded and run Coils to Locs, a textured-wig company for medical hair loss, and the posts show 27-plus hospital and cancer centre partnerships with a stated goal of 40 by the end of 2026, a 'Wigs 101 for Alopecia Areata' webinar for the National Alopecia Areata Foundation, a live presentation and panel at the 41st Annual NAAF Conference in Orlando, an 'Ask For Coils to Locs By Name' campaign running with hospital partners, and a $25,000 Chasm Momentum Grant plus a $1,000 Rockland Trust award. A campaign that needs a collaborator who can speak about patient dignity, oncology nursing, hospital retail, and how a patient-facing product actually gets stocked and recommended is served better here than by a research analyst.

The trade-off is that Pamela Shaddock's posts focus on company progress and event promotion, not trial design or data governance.

• They say nothing about consent design, participant data ownership, IRT systems, ICH GCP, EU CTR 536/2014, or the cost barriers that shape enrolment—areas Jean Stimola-Sposaro covers with named studies and regulatory citations.
• A sponsor commissioning co-authored analysis would need to supply the analytical frame.
• There is also a commercial-adjacency question: the content centres on a business Shaddock co-founded and its hospital partnerships.
• If the sponsor operates near hospital supply or patient-support services, settle independence and disclosure terms up front.

Examples: Source 1 · Source 2

For companies focused on patient voice, cultural safety, or community engagement, Adenipekun brings lived experience of the system alongside formal training in it.

• The posts describe a mother's death from cancer, a sister's later diagnosis and Adenipekun's own, a master's in International Development and Human Rights, and the move into patient advocacy that followed.
• They also feature a book, 'Navigating Your New Normal: A Road Map For Life Fulfilment After Trauma'.
• The clearest working example is the 'Seen Heard Valued' event for 9 September with NHS Wales.
• It centres on the argument that most healthcare community engagement stops at the survey and never returns to say what changed—a point a health-equity campaign can build on.

The trade-off is analytical range.

• Bami Adenipekun's posts focus on personal narrative and event registration.
• A sponsor wanting to make the case about consent-stage drop-off, protocol budgets for travel and caregiver support, or participant data ownership would need to bring the information and framing.
• The posts contain no trial-operations, regulatory, or published-study analysis, and end with a book link and an event sign-up rather than an open question for sponsors.
• That makes Adenipekun a closer fit as a patient-voice speaker or community-programme partner than as a co-author of industry commentary.

Examples: Source 1 · Source 2

The posts show Hussain Mooraj co-hosting the NextGen Therapy EMEA Industry Working Group in Rome and running the 2026 Deloitte NextGen Therapies Industry Working Group Spring Summit at Deloitte University, with named speakers spanning clinical delivery, manufacturing, investment, and AI, and a LinkedIn community hub that people can join to continue the discussion.

• The content is pitched at the access problem at enterprise scale, with specific numbers worth quoting: fewer than one in five eligible patients able to reach these therapies, one company reporting cost of goods under $8,000, 90% of the room using AI daily, and investors now asking how a therapy will reach a patient before they commit.
• For a campaign that needs payer, policy, and manufacturing executives in the audience, this is a more direct route than a research-led commentary series.

The trade-off is independence and evidence style.

• Hussain Mooraj's posts recap convenings hosted through Deloitte's branded programme with Deloitte colleagues; they do not analyse published studies.
• The reach and community hub belong to that programme, not to whoever commissions the work.
• A technology vendor buying vendor-neutral thought leadership would be commissioning commentary about an employer's platform.
• The posts also assert figures without linking the underlying sources, unlike Jean Stimola-Sposaro's, which cite the JMIR Delphi study, the Applied Clinical Trials piece, and the Clinical Trial Modernization Act directly.
• An editor would need to source and verify each claim before publication.

Examples: Source 1 · Source 2